Somnair Sleep

Based in the US, Somnair Sleep specializes in developing innovative neurostimulation devices for treating obstructive sleep apnea, enhancing patient comfort and aiming for effective home-based therapies. Somnair Sleep, founded in 2024 in Towson, US, focuses on addressing obstructive sleep apnea (OSA) with a non-invasive neurostimulation device. The company has raised USD 4. 3 mn in Seed funding as of July 2025, which will be utilized to enhance the technology behind their treatment solutions.

Somnair is pioneering the development of a non-invasive neurostimulation device aimed at addressing the root causes of obstructive sleep apnea (OSA). This innovative solution leverages neurostimulation therapy, which is designed to operate within the comfort of the patient's home. The core product offering focuses on providing an effective treatment for OSA by targeting the neurological mechanisms involved in the condition. Although the device is currently in the pre-clinical development stage and not yet available to the public, it is intended for a diverse range of end users, including patients suffering from OSA and healthcare providers involved in sleep medicine.

The company is targeting various geographical markets, with an emphasis on regions where sleep apnea is a prevalent health issue, including North America and Europe. Somnair's revenue model is anticipated to be structured around direct-to-consumer sales and possibly partnerships with healthcare providers and institutions focused on sleep disorders. The company’s flagship product, the Somnair device, is expected to be marketed as a subscription service or through one-time purchases, reflecting the trend in the medical device industry towards accessible at-home treatment options. Customer transactions may involve initial device costs followed by ongoing subscription fees for software updates, additional support, or ancillary services associated with the neurostimulation therapy.

The specific pricing plans for the Somnair device and associated services are structured in a manner that ensures affordability and accessibility for patients requiring treatment for obstructive sleep apnea, though precise figures are not disclosed. Somnair Sleep plans to leverage its recent Seed funding of USD 4. 3 mn, secured in July 2025, to accelerate the technological advancement of its sleep apnea device. The company is working on developing its product for release in the near future while targeting expansion into North America and Europe, where there is a high prevalence of sleep apnea.

This strategic focus aims to ensure that their innovative solutions reach markets where they can have the most significant impact.